<DOC>
	<DOCNO>NCT01693276</DOCNO>
	<brief_summary>This study analyze effect , good and/or bad , drug Abraxane combination gemcitabine gemcitabine concurrent radiation therapy patient locally advanced pancreatic cancer remove surgery . All medication use study FDA-approved use patient pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine/Abraxane Chemotherapy Dose Escalated Radiotherapy Locally Advanced , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>The long term goal improve survival patient unresectable pancreatic cancer . Additional potential benefit include increase probability local control decrease distant metastasis .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically cytologically proven carcinoma pancreas locally advance ECOG performance status 0 2 Adequate lab No prior abdominal radiation therapy No concurrent clinically evident malignancy , except inactive nonmelanoma skin cancer , inactive cervical cancer , cancer patient diseasefree 5 year All disease must encompass within radiotherapy portal Not pregnant nursing Patient metastatic disease radiological stag systemic therapy . Patient know active infection HIV , hepatitis C hepatitis B Patient serious medical risk factor involve major organ system Investigator considers unsafe patient receive experimental research drug . Patient deem obvious resectable disease presentation Received investigational agent within month prior enrollment . Neuroendocrine tumor pancreas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>